NVTA / Invitae Corporation - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER CONFIRMING THE THIRD AMENDED JOINT PLAN OF INVITAE CORPORATION AND ITS DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE

Exhibit 2.1 Caption in Compliance with D.N.J. LBR 9004-1(b) UNITED STATES BANKRUPTCY COURT DISTRICT OF NEW JERSEY In re: INVITAE CORPORATION, et al.,                 Debtors.1 Chapter 11 Case No. 24-11362 (MBK) (Jointly Administered) FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER CONFIRMING THE THIRD AMENDED JOINT PLAN OF INVITAE CORPORATION AND ITS DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE

Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organizati

UNITED STATES BANKRUPTCY COURT DISTRICT OF NEW JERSEY In re: INVITAE CORPORATION, et al.,                Debtors.1 Chapter 11 Case No. 24-11362 (MBK) (Jointly Administered)

Exhibit 99.1 KIRKLAND & ELLIS LLP KIRKLAND & ELLIS INTERNATIONAL LLP Joshua A. Sussberg, P.C. (admitted pro hac vice) Nicole L. Greenblatt, P.C. (admitted pro hac vice) Francis Petrie (admitted pro hac vice) Jeffrey Goldfine (admitted pro hac vice) 601 Lexington Avenue New York, New York 10022 Telephone: (212) 446-4800 Facsimile: (212) 446-4900 [email protected] nicole.greenblatt@kirkla

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Reporting Perio

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organizatio

Case 24-11362-MBK Doc 701 Filed 06/28/24 Entered 06/28/24 15:22:06  Desc Main Document    Page 1 of 27

Exhibit 99.1 Case 24-11362-MBK Doc 701 Filed 06/28/24 Entered 06/28/24 15:22:06  Desc Main Document    Page 1 of 27 Docket #0701 Date Filed: 06/28/2024 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF NEW JERSEY In Re. Invitae Corporation § Case No. 24-11362 § Lead Case No. 24-11362 § Debtor(s) § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2024 Petiti

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Reporting Perio

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

ASSET PURCHASE AGREEMENT BY AND AMONG LABCORP GENETICS INC., AS PURCHASER, LABORATORY CORPORATION OF AMERICA HOLDINGS, AS GUARANTOR INVITAE CORPORATION AND ITS SUBSIDIARIES NAMED HEREIN, AS SELLERS

Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT BY AND AMONG LABCORP GENETICS INC., AS PURCHASER, LABORATORY CORPORATION OF AMERICA HOLDINGS, AS GUARANTOR AND INVITAE CORPORATION AND ITS SUBSIDIARIES NAMED HEREIN, AS SELLERS TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF THE ACQUIRED ASSETS; ASSUMPTION OF ASSUMED LIABILITIES 1 Section 1.1 Purchase and Sale of the Acquired Assets 1 S

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organizati

Case 24-11362-MBK Doc 390 Filed 04/30/24 Entered 04/30/24 19:59:54  Desc Main Document    Page 1 of 30

Exhibit 99.1 Case 24-11362-MBK Doc 390 Filed 04/30/24 Entered 04/30/24 19:59:54  Desc Main Document    Page 1 of 30 Docket #0390 Date Filed: 04/30/2024 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF NEW JERSEY In Re. Invitae Corporation § Case No. 24-11362 § Lead Case No. 24-11362 Debtor(s) § § ☒ Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2024 Petiti

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Reporting Perio

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 29, 2024 (Date of earliest event reported) Invitae Corporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 29, 2024 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employe

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results SAN FRANCISCO – March 6, 2024 – Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit, and cash burn.

invitae.com© 2024 Invitae Corporation. All Rights Reserved. From genetics, Health Fourth Quarter and Full Year 2023 Estimated Unaudited Financial Results 03.06.2024 2© 2023 Invitae Corporation. All Rights Reserved. Safe harbor statement This presenta

invitae.com© 2024 Invitae Corporation. All Rights Reserved. From genetics, Health Fourth Quarter and Full Year 2023 Estimated Unaudited Financial Results 03.06.2024 2© 2023 Invitae Corporation. All Rights Reserved. Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding In

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 6, 2024 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ("NYSE" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Common Stock of Invitae Corporation (the "Company") from listing and registration on the Exchange on March 4, 2024, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Common Stock is no longer suitable for continued listing and trading on the NYSE.

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process – Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients –

Exhibit 99.1 Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process – Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients – SAN FRANCISCO, Feb. 13, 2024 /PRNewswire/ – Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve i

TRANSACTION SUPPORT AGREEMENT

Exhibit 10.1 THIS TRANSACTION SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. NOTHING CONTAINED IN THIS TRANSACTION SUPPORT AGREEMENT S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Invitae Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

NVTA / Invitae Corporation / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 ef20021446sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec

NVTA / Invitae Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01221-invitaecorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Invitae Corp Title of Class of Securities: Common Stock CUSIP Number: 46185L103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

NVTA / Invitae Corporation / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 4 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

NVTA / Invitae Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Invitae Corpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

Invitae Completes Sale of Reproductive Health Assets to Natera

Invitae Completes Sale of Reproductive Health Assets to Natera SAN FRANCISCO – Jan.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

[TO BE PLACED ON COMPANY LETTERHEAD]

Exhibit 10.1 [TO BE PLACED ON COMPANY LETTERHEAD] Personal and Confidential January [●], 2024 [Employee Name] [Address] Re: Retention Bonus Dear [●]: On behalf of Invitae Corporation (the “Company”), I am pleased to offer you an opportunity to receive a retention bonus of $ (the “Retention Bonus”) if you agree to the terms and conditions of this letter agreement (this “Agreement”). To receive this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Invitae Corpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Invitae Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts – Maintains Minority Equity Stake in Ciitizen – – Anticipated Total Cash Savings of Approximately $90-100 Million on an Annualized Basis –

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts – Maintains Minority Equity Stake in Ciitizen – – Anticipated Total Cash Savings of Approximately $90-100 Million on an Annualized Basis – SAN FRANCISCO – Dec.

ENGAGEMENT AGREEMENT

Exhibit 10.1 ENGAGEMENT AGREEMENT THIS ENGAGEMENT AGREEMENT (the “Agreement”) is made as of December 7, 2023, by and between Invitae Corporation (the “Company”), and Jill Frizzley (“Director”). BACKGROUND WHEREAS, Director has no prior or current affiliation, material business, or relationship, direct or indirect, with the Company or its affiliates, or its equity holders (other than the Advisor Ag

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Invitae Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 Invitae Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on October 18, 2023) Table of Contents

Exhibit 10.4 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on October 18, 2023) Table of Contents SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directors” or “Board” 1 (e) “Cash-Based Award” 1 (f) “Change in Control” 1 (g) “Code” 3 (h) “Committee” 3 (i) “Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2023 (Date of earliest event reported) Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2023 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

Invitae Reports Third Quarter 2023 Financial Results Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of

Invitae Reports Third Quarter 2023 Financial Results Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of 32.2% and non-GAAP gross margin of 52.4%; continued improvement in non-GAAP gross margin for nine consecutive quarters Reaffirming 2023 financial guid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

RETENTION BONUS AGREEMENT

Exhibit 10.5 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (“Agreement”) is made and entered into as of the date of execution by all parties as indicated below, by and between Invitae Corporation (the “Company”) and David Sholehvar. (“Employee”) with respect to the following facts: A.Employee will be and/or is currently employed by the Company as Chief Operating Officer. B.The Company r

INVITAE CORPORATION LONG-TERM RETENTION BONUS AGREEMENT

Exhibit 10.1 INVITAE CORPORATION LONG-TERM RETENTION BONUS AGREEMENT This Long-Term Retention Bonus Agreement (this “Agreement”) is made and entered into effective as of October 19, 2023 (the “Effective Date”), by and between Kenneth D. Knight (“Executive”) and Invitae Corporation, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 1 bel

October 12, 2023

Exhibit 10.4 October 12, 2023 David Sholehvar Re: Offer of Employment with Invitae Corporation Dear David, Congratulations! It is with great pleasure to invite you to join the Invitae team. We look forward to having you join us on November 13, 2023. The terms of our offer are as follows: 1.Duties. As a(n) Regular, full-time employee, your role will be Chief Operating Officer. As Invitae’s business

RETENTION & [**] BONUS AGREEMENT

Exhibit 10.3 [**] Indicates that certain information in this exhibit has been excluded because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. RETENTION & [**] BONUS AGREEMENT This Retention & [**] Bonus Agreement (“Agreement”) is made and entered into as of the date of execution by all parties as indicated below, by and between Invitae Corporat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emp

September 20, 2023

Exhibit 10.1 September 20, 2023 Ana Schrank Re: Offer of Employment with Invitae Corporation Dear Ana, Congratulations! It is with great pleasure to invite you to join the Invitae team. We look forward to having you join us on October 2, 2023 (the “Start Date”). The terms of our offer are as follows: 1. Duties. As a full-time employee, your role will be the sole Chief Financial Officer of Invitae

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Invitae Corpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emp

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard SAN FRANCISCO – September 22, 2023 – Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023, indicating the company is not currently in compliance with Section 802.

NVTA / Invitae Corp / Flynn James E Passive Investment

SC 13G 1 e618907sc13g-nvta.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Invitae Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Invitae Corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employ

EXCHANGE AGREEMENT

Execution Version EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (including the schedules, annexes and exhibits hereto, this “Agreement”), dated as of August 22, 2023, is entered into by and between Invitae Corporation, a Delaware corporation (the “Company”), the guarantors signatory hereto (the “Guarantors”) and Deerfield Partners, L.

FACE OF NOTE

FACE OF NOTE UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.

FIRST SUPPLEMENTAL INDENTURE

Execution Version FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated and effective as of August 22, 2023, by and among INVITAE CORPORATION (the “Company”), the Guarantors referred to in the Indenture (as defined below) and U.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employ

Invitae Corporation Up to $389,987,701 Common Stock

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-263205 PROSPECTUS SUPPLEMENT Invitae Corporation Up to $389,987,701 Common Stock We previously entered into a sales agreement on May 4, 2021, or the Sales Agreement, with Cowen and Company, LLC, or TD Cowen, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the

26,632,735 Shares Invitae Corporation Common Stock

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-256683 PROSPECTUS 26,632,735 Shares Invitae Corporation Common Stock This prospectus relates to the potential sale or disposition from time to time by SB Northstar LP, Chimera Investment LLC and Baker Bros. Advisors LP, or collectively, the selling stockholders of some or all of the shares of common stock, $0.0001 par va

As filed with the Securities and Exchange Commission on August 9, 2023

Table of Contents As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.

EFFECT

X0101 EFFECT 33 LIVE 2023-08-09 0001193125-23-206891 POS AM 0001501134 Invitae Corp 333-256683

As filed with the Securities and Exchange Commission on August 9, 2023

POS AM Table of Contents As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact n

Invitae Reports Second Quarter 2023 Financial Results – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year – – GAAP gross margin was 27.4% and non-G

Invitae Reports Second Quarter 2023 Financial Results – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year – – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annua

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 8, 2023 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Invitae Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

between Invitae Corporation and Christine M. Gorjanc.

Exhibit 10.1 CONSULTING AGREEMENT Pursuant to this Consulting Agreement (this “Agreement”), effective as of June 30, 2023 (the “Effective Date”), Invitae Corporation, a Delaware corporation (the “Company”), and Christine Gorjanc (“Consultant”) hereby agree as follows: 1.Services and Payment. Consultant agrees to provide the services described in Exhibit A attached hereto (the “Services”). As the o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Invitae Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Invitae Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer

Invitae Reports First Quarter 2023 Financial Results – Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% – – Continued improvement in gross marg

Invitae Reports First Quarter 2023 Financial Results – Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% – – Continued improvement in gross margin and ongoing cash burn trends – – Company reiterates key 2023 financial guidance metrics – – Conference call and webcast today at 4:30 p.m. Eastern

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of April 3, 2023.

Exhibit 10.2 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on April 3, 2023) Table of Contents SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directors” or “Board” 1 (e) “Cash-Based Award” 1 (f) “Change in Control” 1 (g) “Code” 3 (h) “Committee” 3 (i) “Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 9, 2023 (Date of earliest event reported) Invitae Corporation (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 9, 2023 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer i

Amended and Restated Certificate of Incorporation of Invitae Corporation, as amended

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INVITAE CORPORATION Invitae Corporation, a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The name of the corporation is Invitae Corporation SECOND: The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the State of Delawa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 INVITAE CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

111,627,888 Shares Invitae Corporation Common Stock

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-270661 PROSPECTUS 111,627,888 Shares Invitae Corporation Common Stock This prospectus relates to the resale from time to time by the selling stockholder identified in this prospectus of up to 111,627,888 shares of our common stock, $0.0001 par value per share, issuable upon conversion of our 4.5% Series B Convertible Sen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Notice of Annual Meeting of Stockholders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Invitae Corporation 1400 16th Street San Francisco, CA 94103 April 19, 2023

CORRESP Invitae Corporation 1400 16th Street San Francisco, CA 94103 April 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 INVITAE CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Notice of Annual Meeting of Stockholders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.

Power of Attorney (included on the signature page hereof).

S-3 Table of Contents As filed with the Securities and Exchange Commission on March 17, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Invitae Corporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organizati

Series A Global Note representing the 4.50% Convertible Senior Secured Notes due 2028 (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on March 8, 2023).

EX-4.2 Exhibit 4.2 FACE OF NOTE UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 Invitae Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation) (Commission File N

Registration Rights Agreement, dated as of March 7, 2023, between Invitae Corporation and the investor party thereto.

EX-10.1 Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 7, 2023, by and among Invitae Corporation, a Delaware corporation (the “Company”), and each of the Investors from time to time signatory hereto. WHEREAS: A. In accordance with the Purchase and Exchange Agreement, dated as of February 28, 2023, by and among the Company, the investo

Indenture, dated as of March 7, 2023, between Invitae Corporation, the guarantor parties thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent

EX-4.1 Exhibit 4.1 Execution Version INVITAE CORPORATION, THE GUARANTORS PARTY HERETO FROM TIME TO TIME, AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as of March 7, 2023 4.5% Series A Convertible Senior Secured Notes due 2028 4.5% Series B Convertible Senior Secured Notes due 2028 TABLE OF CONTENTS Article 1 Definitions 2 Section 1.01 Definitio

Series B Global Note representing the 4.50% Convertible Senior Secured Notes due 2028 (incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed on March 8, 2023).

EX-4.3 Exhibit 4.3 FACE OF NOTE UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST CO

As filed with the Securities and Exchange Commission on February 28, 2023

POS AM Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

Form of Registration Rights Agreement

EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2023, by and among Invitae Corporation, a Delaware corporation (the “Company”), and each of the Investors from time to time signatory hereto. WHEREAS: A. In accordance with the Exchange Agreement, dated as of the date hereof, by and among the Company, the investors from time to time

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation) (Commission Fi

Form of New Notes Indenture

EX-4.1 Exhibit 4.1 INVITAE CORPORATION, THE GUARANTORS PARTY HERETO FROM TIME TO TIME, AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as of March [], 2023 4.5% Series A Convertible Senior Secured Notes due 2028 4.5% Series B Convertible Senior Secured Notes due 2028 TABLE OF CONTENTS Article 1 Definitions 2 Section 1.01 Definitions 2 Section 1.02

As filed with the Securities and Exchange Commission on February 28, 2023

POS AM Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

Form of Purchase and Exchange Agreement

EX-10.1 Exhibit 10.1 Invitae Corporation February 28, 2023 FORM OF PURCHASE AND EXCHANGE AGREEMENT 1. Introduction. Invitae Corporation, a Delaware corporation (the “Company”), proposes (i) to exchange (the “Exchange Transaction”) $[ • ] aggregate principal amount of the Company’s 2.00% Convertible Senior Notes due 2024, CUSIP 46185 LAB9 (the “Old Notes”) held by certain existing holders of the Ol

Form of Warrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on March 1, 2023).

EX-4.2 Exhibit 4.2 [THE OFFER AND SALE OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, EXCEPT PURSUANT TO AN EXEMPTION FROM

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2023 (Date of earliest event reported) Invitae Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2023 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

Power of Attorney.

POSASR Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 Registration Statement Under The Securities Act of 1933 Invitae Corporati

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

List of Subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES OF INVITAE CORPORATION Subsidiary Jurisdiction ArcherDX, LLC Delaware ArcherDX Clinical Services, Inc. Colorado Ciitizen, LLC Delaware Genelex India Private Limited India Genetic Solutions LLC, d/b/a Genelex Pennsylvania Genosity, LLC Delaware Good Start Genetics, Inc. Delaware Invitae Australia PTY LTD Australia Invitae Canada Inc. British Colombia, Canada Invita

Exhibit 4.2

Exhibit 4.2 INVITAE CORPORATION DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Invitae Corporation, a Delaware corporation (“we”, “us” or “our”), has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934: our common stock, $0.0001 par value per share. The general terms and provisions of our common stock

– Repaid its 2024 senior secured term loan in full, improving its balance sheet – – Company maintains cash runway through the end of 2024 – – Annual revenue grew by 12.1%; Continued to improve on key financial metrics – – Major initiatives under stra

Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates – Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) – – Repaid its 2024 senior secured term loan in full, improving its balance sheet – – Company maintains cash runway through the end of 2024 – – Annual revenue grew by 12.

Power of Attorney.

POSASR Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees Previously Paid Equity Common Stock, $0.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact name

NVTA / Invitae Corp / Casdin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NVTA / Invitae Corp / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

NVTA / Invitae Corp / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

NVTA / Invitae Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01180-invitaecorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Invitae Corp. Title of Class of Securities: Common Stock CUSIP Number: 46185L103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

NVTA / Invitae Corp / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 3 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

Invitae Reports Preliminary 2022 Financial Results — Approximately 12% growth year-over-year in revenues — — Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash — — Cash burn continued its declining trend o

Invitae Reports Preliminary 2022 Financial Results — Approximately 12% growth year-over-year in revenues — — Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash — — Cash burn continued its declining trend over the past five quarters — — Presenting at the 41st Annual J.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employ

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission F

Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc. — Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings — — The transac

EX-99.1 Exhibit 99.1 Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc. — Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings — — The transaction contributes to Invitae’s cash runway and includes a strategic supply partnership to support the growth of Invitae Personaliz

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Ex

Transition and Separation Agreement, dated as of July 17, 2022, by and between Invitae Corporation and Sean George

Exhibit 10.2 INVITAE CORPORATION 1400 16th Street San Francisco, California 94103 July 17, 2022 Sean George, Ph.D. Re: Transition and Separation Agreement Dear Dr. George: This letter sets forth the substance of the transition and separation agreement (this “Agreement”) that Invitae Corporation (the “Company”) is offering to you to aid in your employment transition, as well as certain related arra

Change of Control and Severance Agreement, dated July 18, 2022 by and between Invitae Corporation and Kenneth D. Knight

Exhibit 10.1 INVITAE CORPORATION CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control Severance Agreement (this “Agreement”) is made and entered into effective as of July 18, 2022 (the “Effective Date”), by and between Kenneth D. Knight (“Executive”) and Invitae Corporation, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section

Invitae Reports Third Quarter 2022 Financial Results — Continued to execute against realignment plan and portfolio optimization initiatives — — Reported revenue of $133.5 million, a 16.7% YoY increase — — Cash, cash equivalents, restricted cash and m

Invitae Reports Third Quarter 2022 Financial Results — Continued to execute against realignment plan and portfolio optimization initiatives — — Reported revenue of $133.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2022 (Date of earliest event reported) Invitae Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2022 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission Fil

Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022 — Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management — — Recently announced realignment plan is expected to exte

Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022 ? Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management ? ? Recently announced realignment plan is expected to extend the company?s cash runway to the end of 2024; Maintain financial guidance ? Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 9, 2022 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact n

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform — Exiting non-core businesses and geographies to prioritize higher-margin business

Exhibit 99.1 Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform ? Exiting non-core businesses and geographies to prioritize higher-margin business initiatives ? ? Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 ? ? Provides preliminary revenu

1

Exhibit 99.3 Script of Investor Conference Call July 18, 2022, 2:00 PT [Conference Call Operator] [Jack Finks] Thank you, operator, and good afternoon, everyone. Thank you for joining us today. Before we begin, I?d like to remind you that various remarks that we make on this call are not historical and constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Pr

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2022 Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation) (Commission File

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected impact, benefits, parameters, details and timing of the company’s strategi

Corporate Update July 18, 2022 Exhibit 99.2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected impact, benefits, parameters, details and timing of the company?s strategic business realignment or various aspects thereof; the company?s beliefs regarding the potential of its bu

Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on June 8, 2022.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INVITAE CORPORATION Invitae Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on Jan

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File N

Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway — Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million

Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway ? Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million ? ? Broad OPEX controls and portfolio optimization to decrease spend, extend runway through 2023? ? Company lays out path for continued industry-leadi

Portfolio Growth 3/31/2020 6/30/2020 9/30/2020 12/31/2020 3/31/2021 6/30/2021 9/30/2021 12/31/2021 3/31/2022 Channel Active accounts 13,177 13,107 13,483 14,336 14,816 16,194 17,402 18,458 19,436 Active partners 66 74 86 106 120 153 169 178 206 Acces

Portfolio Growth 3/31/2020 6/30/2020 9/30/2020 12/31/2020 3/31/2021 6/30/2021 9/30/2021 12/31/2021 3/31/2022 Channel Active accounts 13,177 13,107 13,483 14,336 14,816 16,194 17,402 18,458 19,436 Active partners 66 74 86 106 120 153 169 178 206 Access Patient population 1,137,220 1,253,204 1,410,120 1,597,940 1,797,421 2,029,617 2,274,022 2,528,533 2,825,749 Patient Growth 58% 58% 59% 59% 60% 61% 62% 62% 62% Number of patients available for sharing 664,276 730,924 829,360 947,749 1,086,668 1,242,986 1,408,684 1,576,047 1,750,808 Economics Revenue per patient 420$ 398$ 438$ 535$ 519$ 501$ 468$ 476$ 416$ New product vitality 64.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 3, 2022 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Proxy Statement PROPOSAL 1 Election of Directors Officers Executive Compensation Security Ownership of Certain Beneficial Owners and Management Report of the Audit Committee PROPOSAL 2 Amendment to our Certificate of Incorporation to Increase the Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Proxy Statement PROPOSAL 1 Election of Directors Officers Executive Compensation Security Ownership of Certain Beneficial Owners and Management Report of the Audit Committee PROPOSAL 2 Amendment to our Certificate of Incorporation to Increase the Num

PRE 14A 1 lnvta2022pre14a.htm INVITAE CORP - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission On

Filing Fee Table.

EX-FILING FEES 2 exhibit107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrat

As filed with the Securities and Exchange Commission on March 2, 2022

Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No.

Form of Indenture relating to debt securities (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-3ASR filed on March 2, 2022).

Exhibit 4.1 INVITAE CORPORATION TO [ ] Trustee Indenture Dated as of , 20 INVITAE CORPORATION Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections ? 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 ? 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) ? 312(a) 701 702(a) (b)

$400,000,000 Invitae Corporation Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263205 PROSPECTUS SUPPLEMENT (To Prospectus dated March 2, 2022) $400,000,000 Invitae Corporation Common Stock We previously entered into a sales agreement on May 4, 2021, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, $0.0001 par value per share, offered by this prospect

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo

As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 Registration Statement Under The Securities Act of 1933 Invitae Corporation (

As filed with the Securities and Exchange Commission on March 2, 2022 Registration No.

Calculation of Filing Fee Tables (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Invitae Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Fees Previously Paid Carry Forward Securities Carry Forward Securities Equity Common Stock, $0.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact name

List of Subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES OF INVITAE CORPORATION Subsidiary Jurisdiction ArcherDX, LLC Delaware ArcherDX Clinical Services, Inc. Colorado Ciitizen, LLC Delaware Genelex India Private Limited India Genetic Solutions LLC, d/b/a Genelex Pennsylvania Genosity, LLC Delaware Good Start Genetics, Inc. Delaware Invitae Australia PTY LTD Australia Invitae Canada Inc. British Colombia, Canada Invita

Registrations Rights Agreement, dated as of February 8, 2021, by and among the Invitae Corporation and certain securityholders of Reference Genomics, Inc. d/b/a One Codex.

REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of February 8, 2021 (the ?Effective Date?) by and among Invitae Corporation, a Delaware corporation (the ?Company?), and certain securityholders of Reference Genomics, Inc.

Stratify Genomics Inc. 2018 Equity Incentive Plan, as amended by Amendment No. 1 and Amendment No. 2.

SNP BIO, INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the interests of such pers

Registration Rights Agreement, dated as of September 13, 2021, by and among Invitae Corporation and certain stockholders of Ciitizen Corporation.

ACTIVE/111903608.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 13, 2021 (the ?Effective Date?) by and among Invitae Corporation, a Delaware corporation (the ?Company?), and certain securityholders of Ciitizen Corporation, a Delaware corporation (?Ciitizen?) listed on Exhibit A hereto (each such securityholder, as well

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 24, 2022 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021 — Annual revenue grew by 65 percent and annual billable volume by 77 percent year over year — — Full-year 2022 revenue growth guidance of 40 percent to

Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021 ? Annual revenue grew by 65 percent and annual billable volume by 77 percent year over year ? ? Full-year 2022 revenue growth guidance of 40 percent to approximately $640 million ? ? Guiding to expansion of gross margin throughout 2022 and decreasing cash burn charting path to positive cash flows ? ?

NVTA / Invitae Corp / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment

SC 13G/A 1 brhc10033963sc13ga.htm SC13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Che

NVTA / Invitae Corp / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

NVTA / Invitae Corp / Casdin Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NVTA / Invitae Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Invitae Corp. Title of Class of Securities: Common Stock CUSIP Number: 46185L103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

NVTA / Invitae Corp / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

NVTA / Invitae Corp / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million

EX-99.1 2 d292306dex991.htm EX-99.1 Exhibit 99.1 Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million • 64 percent growth year-over-year in revenues • 76 percent growth year-over-year in billable volumes • Ended the year with more than 17,500 active healthcare provider accounts • Active pharma and commercial partnerships expand by 68 perc

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission Fi

Stratify Genomics Inc. 2018 Equity Incentive Plan, as amended by Amendment No. 1 and Amendment No. 2.

Exhibit 99.1 SNP BIO, INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the interests

As filed with the Securities and Exchange Commission on December 28, 2021

As filed with the Securities and Exchange Commission on December 28, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Ex

Amendment No. 2, dated as of September 20, 2021, by and among Invitae Corporation, the subsidiary guarantors from time to time party thereto, the lenders party thereto and Perceptive Credit Holdings III, LP, as the Administrative Agent, to Credit Agreement and Guaranty, dated as of October 2, 2020, by and among Invitae Corporation, the subsidiary guarantors from time to time party thereto, the lenders party thereto and Perceptive Credit Holdings III, LP, as the Administrative Agent.

Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY, dated as of September 20, 2021 (this ?Amendment?), is by and among INVITAE CORPORATION, a Delaware corporation (the ?Borrower?), the Subsidiary Guarantors party hereto, the Lenders party hereto, and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership

Form of Global Restricted Stock Unit Agreement under the Invitae Corporation 2015 Stock Incentive Plan.

Exhibit 10.4 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD You have been granted the following restricted Stock Units (?Restricted Stock Units?) representing common stock of Invitae Corporation (the ?Company?) under the Company?s 2015 Stock Incentive Plan (as may be amended from time to time, the ?Plan?). Capitalized terms not defined herein have the meanings

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of August 31, 2021.

Exhibit 10.3 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on August 31, 2021) Table of Contents SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) ?Affiliate? 1 (b) ?Award? 1 (c) ?Award Agreement? 1 (d) ?Board of Directors? or ?Board? 1 (e) ?Cash-Based Award? 1 (f) ?Change in Control? 1 (g) ?Code? 3 (h) ?Committee? 3 (i) ?Compa

Invitae Corporation Employee Stock Purchase Plan, as amended and restated as of October 14, 2021.

Exhibit 10.2 INVITAE CORPORATION EMPLOYEE STOCK PURCHASE PLAN TABLE OF CONTENTS SECTION 1 Purpose of the Plan 1 SECTION 2 Definitions 1 (a) ?Affiliate? 1 (b) ?Board? 1 (c) ?Cashless Participation Program? 1 (d) ?Cashless Participation Program Provider? 1 (e) ?Code? 1 (f) ?Committee? 1 (g) ?Company? 1 (h) ?Compensation? 1 (i) ?Corporate Reorganization? 2 (j) ?Eligible Employee? 2 (k) ?Exchange Act?

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. emplo

Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021 — Q3 2021 revenue increases more than 66% on volume growth of 89% from Q3 2020 — — Full-year 2021 revenue expected to grow 60-70%, or between $450

Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021 ? Q3 2021 revenue increases more than 66% on volume growth of 89% from Q3 2020 ? ? Full-year 2021 revenue expected to grow 60-70%, or between $450-$475 million ? ? Hosting conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time ? SAN FRANCISCO, November 8, 2021 ? Inv

NVTA / Invitae Corp / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Registration Rights Agreement, dated as of September 13, 2021, by and among the Registrant and certain stockholders of Citizen Corporation.

Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 13, 2021 (the ?Effective Date?) by and among Invitae Corporation, a Delaware corporation (the ?Company?), and certain securityholders of Ciitizen Corporation, a Delaware corporation (?Ciitizen?) listed on Exhibit A hereto (each such securityholder, as well as any

As filed with the Securities and Exchange Commission on September 15, 2021

Table of Contents As filed with the Securities and Exchange Commission on September 15, 2021 Registration No.

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of August 31, 2021.

EX-99.1 4 d221039dex991.htm EX-99.1 Exhibit 99.1 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on August 31, 2021) Table of Contents SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Award Agreement” 1 (d) “Board of Directors” or “Board” 1 (e) “Cash-Based Award” 1 (f) “Change in Control” 1 (g) “

As filed with the Securities and Exchange Commission on September 14, 2021

As filed with the Securities and Exchange Commission on September 14, 2021 Registration No.

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research — Ciitizen platform will empower patients to securely collect, organize and benefit from their full range of health

Exhibit 99.1 Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research ? Ciitizen platform will empower patients to securely collect, organize and benefit from their full range of health data ? ? Combination to bring together the power of genomic and clinical information within a new kind of patient data platform to improv

Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission F

Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s beliefs regarding the potential benefits of its pen

Acquisition and platform update 09 | 07 | 21 From genetics, health + Exhibit 99.2 Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company?s beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the co

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Change in Control and Severance Agreement, between Invitae Corporation and Sean George.

Exhibit 10.5 INVITAE CORPORATION CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control Severance Agreement (this ?Agreement?) is made and entered into effective as of April 23, 2021 (the ?Effective Date?), by and between Sean George (?Executive?) and Invitae Corporation, a Delaware corporation (the ?Company?). Certain capitalized terms used in this Agreement are defined in Section 1 bel

Form of Change in Control and Severance Agreement, between Invitae Corporation and certain officers.

Exhibit 10.6 INVITAE CORPORATION CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Change of Control Severance Agreement (this ?Agreement?) is made and entered into effective as of (the ?Effective Date?), by and between (?Executive?) and Invitae Corporation, a Delaware corporation (the ?Company?). Certain capitalized terms used in this Agreement are defined in Section 1 below. RECITALS A. It is expec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact n

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of July 16, 2021.

Exhibit 99.1 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on July 16, 2021) Table of Contents SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) ?Affiliate? 1 (b) ?Award? 1 (c) ?Award Agreement? 1 (d) ?Board of Directors? or ?Board? 1 (e) ?Cash-Based Award? 1 (f) ?Change in Control? 1 (g) ?Code? 3 (h) ?Committee? 3 (i) ?Company

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 3, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employe

Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021 — Increased quarterly revenue by 152% year-over-year — —Increases guidance of revenue between $475-$500 million in 2021 — — Hosting conference ca

Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021 ? Increased quarterly revenue by 152% year-over-year ? ?Increases guidance of revenue between $475-$500 million in 2021 ? ? Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific ? SAN FRANCISCO, August 3, 2021 ? Invitae Corporation (NYSE: NVTA), a leading medical genetics c

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File N

Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer

Exhibit 99.1 Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer SAN FRANCISCO, June 11, 2021 ? Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global technology and medical tech

between Invitae Corporation and Roxi Wen.

EX-10.1 2 d141350dex101.htm EX-10.1 Exhibit 10.1 May 19, 2021 Roxi Wen San Jose, CA Re: Offer of Employment with Invitae Corporation Dear Roxi, It is with great pleasure to invite you to join the Invitae team. We look forward to having you join us on June 21, 2021. The terms of our offer are as follows: 1. Duties. As a full time employee, your role will be Chief Financial Officer. As Invitae’s bus

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File N

As filed with the Securities and Exchange Commission on June 1, 2021

Table of Contents As filed with the Securities and Exchange Commission on June 1, 2021 Registration No.

- S-8

As filed with the Securities and Exchange Commission on May 4, 2021 Registration No.

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, $0.0001 par value per share $400,000,000 $43,640

424B5 1 d160136d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230053 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, $0.0001 par value per share $400,000,000 $43,640 (1) Estimated solely for the purpose of computing the amount of the

Registration Rights Agreement, dated as of April 16, 2021, by and among the Registrant and certain securityholders of Genosity Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021).

Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 16, 2021 (the ?Effective Date?) by and among Invitae Corporation, a Delaware corporation (the ?Company?), and certain securityholders of Genosity Inc., a Delaware corporation (?Genosity?) listed on Exhibit A hereto (each such securityholder, as well as any permitted

- S-3ASR

Table of Contents As filed with the Securities and Exchange Commission on May 4, 2021 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 4, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. employer i

Sales Agreement, dated as of May 4, 2021, between the Registrant and Cowen and Company, LLC (incorporated by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed on May 5, 2021).

Exhibit 1.1 INVITAE CORPORATION COMMON STOCK SALES AGREEMENT May 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Invitae Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the te

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of March 26, 2021.

Exhibit 10.1 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on March 26, 2021) SECTION 1.ESTABLISHMENT AND PURPOSE. The Plan was adopted by the Board of Directors on January 8, 2015 and became effective immediately prior to the closing of the initial offering of Stock to the public pursuant to a registration statement filed by the Company with the

Invitae Reports $103.6 Million in Revenue Driven by 259,000 in Billable Volume in First Quarter of 2021 — Increased quarterly revenue by 61% and volume by 72% year-over-year — — Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacif

Invitae Reports $103.6 Million in Revenue Driven by 259,000 in Billable Volume in First Quarter of 2021 ? Increased quarterly revenue by 61% and volume by 72% year-over-year ? ? Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific ? SAN FRANCISCO, May 4, 2021 ? Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating result

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact

- INVITAE CORP - DEFA14A

DEFA14A 1 lnvta2021defa14a.htm INVITAE CORP - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission O

- INVITAE CORP - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Lease Agreement, dated as of April 20, 2021, by and between Invitae Corporation and APB Owned LLC.

Exhibit 10.1 AGREEMENT OF LEASE By and Between APB OWNER LLC (?Landlord?) and INVITAE CORPORATION (?Tenant?) * * * * * * 1001 Airport Boulevard Morrisville, NC April 20, 2021 TABLE OF CONTENTS Page 1. BASIC LEASE PROVISIONS 1 2. COMMENCEMENT, TERM & RENEWAL RIGHTS 6 3. USE 7 4. RENT 8 6. UTILITIES 11 7. LANDLORD?S REPAIRS AND MAINTENANCE 12 8. TENANT?S REPAIRS AND MAINTENANCE; OPERATION OF THE INT

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Indenture, dated as of April 8, 2021, between the Registrant and U.S. Bank National Association (including form of Note) (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on April 8, 2021).

Exhibit 4.1 INVITAE CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 8, 2021 1.50% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount 14 Section 2.02. Fo

Amendment No. 1, dated as of April 3, 2021, by and among Invitae Corporation, the subsidiary guarantors from time to time party thereto, the lenders party thereto and Perceptive Credit Holdings III, LP, as the Administrative Agent, to Credit Agreement and Guaranty, dated as of October 2, 2020, by and among Invitae Corporation, the subsidiary guarantors from time to time party thereto, the lenders party thereto and Perceptive Credit Holdings III, LP, as the Administrative Agent.

Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of April 3, 2021 (this ?Amendment?), is by and among INVITAE CORPORATION, a Delaware corporation (the ?Borrower?), the Subsidiary Guarantors party hereto, the Lenders party hereto, and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership, as

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

EX-99.4 Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements are based on the historical consolidated financial statements of Invitae Corporation (“Invitae”, “we,” “our” or “us) and ArcherDX Inc. (“ArcherDX”); and are adjusted to give effect to the October 2020 merger of ArcherDX with and into a wholly-o

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporat

Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives

EX-99.1 Exhibit 99.1 Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives SAN FRANCISCO, April 5, 2021 — Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Group Corp., will make an investment of $1.15 billion in convertible senior notes to support the Company’s future

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commission File

Investment Agreement, dated as of April 3, 2021, by and among Invitae Corporation and parties listed therein (including form of Indenture relating to 1.50% Convertible Senior Notes due 2028).

Exhibit 10.1 EXECUTION VERSION INVESTMENT AGREEMENT by and among INVITAE CORPORATION and the parties listed herein Dated as of April 3, 2021 TABLE OF CONTENTS Page ARTICLE I. 1 Section 1.01 Definitions 1 Section 1.02 General Interpretive Principles 9 ARTICLE II. 9 Section 2.01 Sale and Purchase of the Notes 9 Section 2.02 Closing 10 Section 2.03 Termination 12 ARTICLE III. 13 Section 3.01 Represen

Amended and Restated Bylaws.

Exhibit 3.1 AMENDED AND RESTATED B Y L A W S OF INVITAE CORPORATION (a Delaware corporation) (As amended as of March 23, 2021) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 3 2.4 Notice of Meetings 3 2.5 List of Stockholders 3 2.6 Organization and Conduct of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 23, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organization)

Registration Rights Agreement, dated as of February 8, 2021, by and among the Registrant and certain securityholders of Reference Genomics, Inc. d/b/a One Codex.

Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of February 8, 2021 (the ?Effective Date?) by and among Invitae Corporation, a Delaware corporation (the ?Company?), and certain securityholders of Reference Genomics, Inc. d/b/a One Codex, a Delaware corporation (?One Codex?) listed on Exhibit A hereto (each such securityhol

- S-8

As filed with the Securities and Exchange Commission on February 26, 2021 Registration No.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36847 Invitae Corporation (Exact name

ArcherDX, Inc. 2015 Equity Incentive Plan, as amended, and forms of agreements thereunder

Exhibit 10.21 ARCHERDX, INC. 2015 STOCK INCENTIVE PLAN1 1. Purpose The purpose of this 2015 Stock Incentive Plan (the ?Plan?) of ArcherDx, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing s

- S-3ASR

Table of Contents As filed with the Securities and Exchange Commission on February 26, 2021 Registration No.

Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).

Exhibit 4.1

Registration Rights Agreement, dated as of December 8, 2020, by and between Invitae Corporation and IntelliGene Health Informatics, LLC.

Exhibit 4.14 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of December 8, 2020 (the ?Effective Date?) by and between Invitae Corporation, a Delaware corporation (the ?Company?), and IntelliGene Health Informatics, LLC, a California limited liability company (?Seller?). RECITALS WHEREAS, concurrently herewith, the Company and Seller

List of Subsidiarie

Exhibit 21.1 LIST OF SUBSIDIARIES OF INVITAE CORPORATION Subsidiary Jurisdiction ArcherDX, LLC Delaware Archer DX Clinical Services, Inc. Colorado Clear Genetics, Inc. Delaware CombiMatrix Corporation Delaware CombiMatrix Molecular Diagnostics, Inc. California Genelex India Private Limited India Genetic Solutions LLC, d/b/a Genelex Pennsylvania Good Start Genetics, Inc. Delaware Jungla, LLC Delawa

Invitae Corporation 2015 Stock Incentive Plan, as amended and restated as of December 7, 2020.

Exhibit 10.5 INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN (As Amended and Restated by the Board of Directors on December 7, 2020) INVITAE CORPORATION 2015 STOCK INCENTIVE PLAN SECTION 1.ESTABLISHMENT AND PURPOSE. The Plan was adopted by the Board of Directors on January 8, 2015 and became effective immediately prior to the closing of the initial offering of Stock to the public pursuant to a regis

- S-3ASR

Table of Contents As filed with the Securities and Exchange Commission on February 26, 2021 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 17, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of the registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of (Commission (I.R.S. empl

Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020 -- Increased annual revenue by 29% and annual billable volume by 41% year-over-year -- -- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm

Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020 - Increased annual revenue by 29% and annual billable volume by 41% year-over-year - - Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - SAN FRANCISCO, February 17, 2021 – Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operati

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Invitae Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) (CUSIP Num

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Invitae Corporation (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invitae Corporation

SC 13G/A 1 brhc10020197sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Invitae Corp. Title of Class of Securities: Common Stock CUSIP Number: 46185L103 Date of Event Which Requires Filing of this Statement: January 29, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Invitae Corp. Title of Class of Securities: Common Stock CUSIP Number: 46185L103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invitae Corporation (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 3, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organization

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 21, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organization

Underwriting Agreement dated as of January 21, 2021 among the Company and J.P. Morgan Securities, LLC, Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters.

EX-1.1 Exhibit 1.1 INVITAE CORPORATION 7,766,990 Shares of Common Stock, $0.0001 par value per share Underwriting Agreement January 21, 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585

Invitae Announces Pricing of Public Offering of Common Stock

EX-99.1 Exhibit 99.1 Invitae Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, January 21, 2021 — Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before d

Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering

EX-99.2 5 d113054dex992.htm EX-99.2 Exhibit 99.2 Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering SAN FRANCISCO, January 26, 2021 — Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sol

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.0001 par

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230053 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.0001 par value per share 8,932,038 $51.50 $459,999,957 $50,186 (1) Include

Invitae Announces Proposed Public Offering of Common Stock

EX-99.1 2 d113105dex991.htm EX-99.1 Exhibit 99.1 Invitae Announces Proposed Public Offering of Common Stock SAN FRANCISCO, January 20, 2021 — Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are

Reconciliation of preliminary estimated GAAP cost of revenue to non-GAAP cost of revenue (in millions) Three months ended December 31, 2020 Year ended December 31, 2020 Lower Upper Lower Upper GAAP cost of revenue $ 67.2 $ 70.7 $ 197.2 $ 200.7 Amorti

EX-99.2 Exhibit 99.2 Our Company We are in the business of delivering genetic testing services that support a lifetime of patient care – from inherited disease diagnoses, to family planning, to proactive health screening to the personalized diagnosis, treatment and monitoring of cancer. Our tests are delivered via a unique, rapidly expanding platform that serves patients, healthcare providers, pay

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 20, 2021 (Date of earliest event reported) Invitae Corporation (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or other jurisdiction of incorporation or organization

Reconciliation of preliminary estimated GAAP cost of revenue to non-GAAP cost of revenue (in millions) Three months ended December 31, 2020 Year ended December 31, 2020 Lower Upper Lower Upper GAAP cost of revenue $ 67.2 $ 70.7 $ 197.2 $ 200.7 Amorti

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-230053 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Subject to completion, dated January 20, 2

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 INVITAE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36847 27-1701898 (State or Other Jurisdiction of Incorporation) (Commissio